Background {#Sec1}
==========

Overactive bladder (OAB) is a symptom complex of storage lower urinary tract symptoms (LUTS) characterized by the presence of urgency. It affects all ages, but is increasingly prevalent as age increases \[[@CR1]--[@CR4]\]. According to the National Overactive Bladder Evaluation (NOBLE) study, prevalence of OAB in those ≥65 years is around 30%, twice as prevalent as in those ≤45 years \[[@CR2]\]. By 2025, it is estimated that there will be 52 million adults in the USA with LUTS \[[@CR5]\]. The older patient population with OAB has high levels of concomitant medication use and comorbidity, is more likely to experience falls and fractures, and is at increased risk of impairment of activities of daily living \[[@CR6]--[@CR8]\]. However, frail elderly patients with multiple comorbidities are often excluded from clinical trials \[[@CR9]--[@CR11]\].

Antimuscarinics are used to treat OAB, however, the risk of anticholinergic adverse events (AEs) such as dry mouth and constipation increases with age \[[@CR12]\]. Exposure to medications with anticholinergic properties has also been linked to adverse cognitive effects, in particular in patients ≥65 years \[[@CR13]\]. Furthermore, older people are particularly sensitive to anticholinergic effects as a result of significant age-related decrease in cholinergic neurons/receptors in the brain, reduction in hepatic and renal clearance of medications, and increase in blood-brain barrier (BBB) permeability \[[@CR14]\]. In addition, the older patient population is likely to be receiving polypharmacy including other drugs with anticholinergic activity (e.g. tricyclic antidepressants, bronchodilators, ACE inhibitors, and antipsychotics), potentially resulting in a problematic anticholinergic burden, with negative effects on cognitive performance \[[@CR15]\]. As a result, the Beers criteria lists all antimuscarinic drugs used for the treatment of OAB as potentially inappropriate for first-line treatment in those ≥65 years of age with dementia or cognitive impairment \[[@CR16]\].

There are several screening instruments to detect dementia and cognitive impairment, including the Mini-Mental State Examination (MMSE) \[[@CR17]\], the Geriatric Mental State Examination \[[@CR18]\] and the Montreal Cognitive Assessment (MoCA) \[[@CR19]\]. The 30-item MoCA, a brief cognitive screening tool for mild cognitive impairment (MCI), is recognized as a sensitive measure of cognitive function that can capture declines in cognition over repeated administrations. The MoCA is scaled from 1 to 30, with higher MoCA scores indicating better cognitive function; a MoCA score \<26 indicates impaired cognitive function \[[@CR19]\]. The MoCA includes six cognitive domains, including visuospatial abilities; language; combined attention, concentration, and working memory; executive function; short-term memory recall; and orientation to time and place, although subsequent consensus has emerged that the total score is most meaningful. The MoCA was conceptualized as an improvement over the MMSE, which does not allow for discrimination between those with MCI and elderly adults with no cognitive impairment. The original context for the MoCA was as a clinical tool, serving front-line physicians in making an initial assessment of MCI.

Mirabegron is a β~3~-adrenoreceptor agonist that represents an alternative OAB treatment to antimuscarinics, and potentially has a more favorable benefit-to-risk ratio in older patient populations \[[@CR20]--[@CR23]\]. The PILLAR study compared flexibly-dosed mirabegron versus placebo in community-dwelling elderly patients ≥65 years with OAB and incontinence \[[@CR24]\]. Statistically significant mean improvements in bladder diary parameters were observed for mirabegron versus placebo, and safety and tolerability were in line with the mirabegron safety profile. The PILLAR study is the first to use MoCA to detect potential cognitive decline related to OAB treatment and aimed to measure any differences in change from baseline of MoCA scores between mirabegron and placebo.

Methods {#Sec2}
=======

Full methods are described in the PILLAR primary paper \[[@CR24]\], but, in brief, PILLAR was a phase 4, multicentre, 12-week study in the US and Canada. Independent Ethics Committee/Institutional Review Board-approved written informed consent was obtained from all participants or their legally authorized representatives. This study adheres to CONSORT guidelines. Community-dwelling patients aged ≥65 years with wet OAB (≥1 incontinence episode and ≥3 urgency episodes during the 3-day diary, plus an average of ≥8 micturitions/24 h), were randomized in a 1:1 fashion to receive mirabegron or placebo. There were no specific exclusion criteria regarding cognitive status, although patients needed to be able to complete the micturition diaries and questionnaires. Patient-reported medical/surgical history was used to identify comorbidities. Patients who were randomized to mirabegron initially received 25 mg/day, with an optional increase to 50 mg/day after week 4/8 based on patient/investigator discretion. The study was designed and powered to detect a difference on incontinence and micturition frequency between combined mirabegron and placebo groups, and was not powered to detect a difference in MoCA scores. Data are displayed as placebo versus total mirabegron and according to treatment group. The safety analysis set (SAF) included all randomized patients receiving at least 1 dose of study medication. AEs were recorded throughout the study until week 16 (4 weeks post end of treatment \[EoT\]). The MoCA was the sole safety endpoint for which inferential comparison was pre-specified in the PILLAR statistical analysis plan. Stratified rank analysis of covariance with change in score from baseline was the response variable, with treatment group and gender as fixed factors. An additional ANCOVA included treatment, gender, and MoCA score at baseline as covariates. The MoCA was conducted at baseline and EoT, week 12, by clinic staff trained in its administration, in either English or Canadian French. Information on education level was not collected directly; however, clinic staff were instructed to add 1 point for any participants with ≤12 years education, as per the original MoCA scoring instructions \[[@CR19]\]. Differences in change from baseline of MoCA scores between mirabegron and placebo were analyzed using a stratified ANCOVA model. As a complement to the pre-specified analyses, a post hoc analysis of relative risk was conducted to determine the relative risk of change in MoCA score by at least 4 points, which is deemed the minimum detectable change (MDC) \[[@CR25]\]. Other post hoc analyses were change from baseline to EoT by baseline medical history of depression or antidepressant medication use, or by presence of ≥1 strong anticholinergic concomitant medication.

Results {#Sec3}
=======

Baseline {#Sec4}
--------

Of the 2380 patients screened, 445 were randomized to mirabegron and 443 to placebo; one patient in the placebo group did not receive treatment (Table [1](#Tab1){ref-type="table"}). Of the 887 randomized patients who received ≥1 dose of study drug, overall 72.3% were female, 79.5% were white, and 28.1% were aged ≥75 years. In total, 226 patients received mirabegron 25 mg and only 219/445 patients (49.2%) uptitrated to 50 mg. There were no meaningful differences in demographic characteristics at baseline between the total mirabegron group and the placebo group. All patients had ≥1 comorbidity and 94.3% were receiving ≥1 concomitant medication; those relevant to cognition are shown in Table [2](#Tab2){ref-type="table"}. One third of patients in the SAF had a history of psychiatric disorders, the most common being depression (17.2%), insomnia (15.7%), and anxiety (11.4%). Charlson Comorbidity Index scores (mean ± SD) were low: 2.3 ± 1.2 for both groups (Table [1](#Tab1){ref-type="table"}). Table 1Baseline characteristics (safety analysis set)Placebo (*n* = 442)Mirabegron Total (*n* = 445)Female sex, *n* (%)324 (73.3)317 (71.2)Age, mean ± SD71.9 ± 6.071.7 ± 5.5Age ≥75 years, *n* (%)124 (28.1)125 (28.1)BMI, kg/m^2^, mean ± SD30.2 ± 6.429.7 ± 6.3 Category, *n* (%)  \<2591 (20.6)108 (24.3)  ≥25--\<30150 (33.9)157 (35.3)  ≥30201 (45.5)180 (40.4)Ethnicity, *n* (%) Not Hispanic or Latino395 (89.4)401 (90.1) Hispanic or Latino43 (9.7)41 (9.2) Unknown4 (0.9)3 (0.7)Race, *n* (%) White357 (80.8)348 (78.2) Asian54 (12.2)59 (13.3) Black or African American25 (5.7)33 (7.4) Other6 (1.4)5 (1.1)Country, *n* (%) United States389 (88.0)385 (86.5) Canada53 (12.0)60 (13.5)Charlson Comorbidity Index score, mean ± SD2.3 (1.2)2.3 (1.2)History of psychiatric disorders Depression72 (16.3)81 (18.2) Insomnia82 (18.6)57 (12.8) Anxiety42 (9.5)59 (13.3) Sleep disorder5 (1.1)6 (1.3) Attention deficit/hyperactivity disorder4 (0.9)4 (0.9) Libido decreased4 (0.9)4 (0.9) Bipolar disorder3 (0.7)4 (0.9) Nicotine dependence5 (1.1)1 (0.2) Adjustment disorder with depressed mood2 (0.5)1 (0.2) Initial insomnia02 (0.4) Persistent depressive disorder02 (0.4) Stress02 (0.4) Major depression1 (0.2)1 (0.2) Adjustment disorder01 (0.2) Alcoholism01 (0.2) Burnout syndrome01 (0.2) Depressed mood01 (0.2) Drug abuse01 (0.2) Drug dependence01 (0.2) Emotional disorder01 (0.2) Mood swings01 (0.2) Nervousness01 (0.2) Post-traumatic stress disorder01 (0.2) Premature ejaculation01 (0.2) Anxiety disorder1 (0.2)0 Claustrophobia1 (0.2)0 Obsessive-compulsive disorder1 (0.2)0MoCA total score^a^, *n* (%) Category, *n* (%)  Normal (≥26)305 (69.3)310 (70.0)  Mild (18--25)103 (23.4)112 (25.3)  Moderate (10--17)3 (0.7)3 (0.7)  Severe (\<10)00  Missing29 (6.6)18 (4.1)Safety analysis set (SAF): all randomized subjects who received ≥1 dose of study medication*MoCA* Montreal Cognitive Assessment, *SD* standard deviation^a^*N* = 440 for placebo and 443 for mirabegron totalTable 2Concomitant non-OAB medications relevant to cognition during double-blind treatment period*n* (%)Placebo (*n* = 442)Mirabegron Total (*n* = 445)CONCOMITANT ANTIDEPRESSANTS SSRIs54 (12.2)53 (11.9)  Citalopram14 (3.2)9 (2.0)  Sertraline11 (2.5)4 (0.9)  Escitalopram oxalate5 (1.1)8 (1.8)  Escitalopram5 (1.1)7 (1.6)  Fluoxetine8 (1.8)4 (0.9)  Citalopram hydrobromide3 (0.7)6 (1.3)  Paroxetine1 (0.2)6 (1.3)  Sertraline hydrochloride4 (0.9)3 (0.7)  Fluoxetine hydrochloride3 (0.7)3 (0.7)  Paroxetine hydrochloride03 (0.7) Other antidepressants23 (5.2)31 (7.0)  Trazodone13 (2.9)17 (3.8)  Duloxetine3 (0.7)4 (0.9)  Duloxetine hydrochloride4 (0.9)2 (0.4)  Mirtazapine2 (0.5)3 (0.7)  Trazodone hydrochloride03 (0.7)  Venlafaxine hydrochloride2 (0.5)1 (0.2)  Desvenlafaxine succinate01 (0.2)  Nefazodone01 (0.2)  Oxitriptan01 (0.2)  Venlafaxine1 (0.2)0  Vortioxetine1 (0.2)0 Non-selective monoamine reuptake inhibitors7 (1.6)9 (2.0)  Amitriptyline2 (0.5)7 (1.6)  Doxepin1 (0.2)1 (0.2)  Nortriptyline2 (0.5)0  Amitriptyline hydrochloride01 (0.2)  Imipramine1 (0.2)0  Nortriptyline hydrochloride1 (0.2)0 Diazepines, oxazepines, thiazepines and oxepines3 (0.7)1 (0.2)  Quetiapine fumarate3 (0.7)1 (0.2) Other antipsychotics02 (0.4)  Aripiprazole01 (0.2)  Risperidone01 (0.2)CONCOMITANT ANTICHOLINERGICS Antihistamines for systemic use38 (8.6)41 (9.2)  Hydroxyzine2 (0.5)2 (0.4)  Hydroxyzine hydrochloride1 (0.2)1 (0.2) Aminoalkyl ethers15 (3.4)16 (3.6)  Diphenhydramine hydrochloride10 (2.3)11 (2.5)  Diphenhydramine4 (0.9)4 (0.9)  Dimenhydrinate1 (0.2)1 (0.2)  Carbinoxamine maleate01 (0.2) Piperazine derivatives3 (0.7)2 (0.4)  Meclozine2 (0.5)1 (0.2) Phenothiazine derivatives1 (0.2)1 (0.2)  Promethazine1 (0.2)0  Promethazine hydrochloride01 (0.2) Substituted alkylamines02 (0.4)  Chlorphenamine maleate02 (0.4) Cough and cold preparations17 (3.8)20 (4.5)  Promethazine with codeine01 (0.2) Carbamic acid esters5 (1.1)1 (0.2)  Carisoprodol2 (0.5)1 (0.2) Synthetic anticholinergics, esters with tertiary amine groups02 (0.4)  Dicycloverine hydrochloride02 (0.4)*OAB* overactive bladder*, SSRIs* selective serotonin reuptake inhibitors

Baseline mean (standard error, SE) MoCA total scores were 26.9 (0.1) and 26.8 (0.1) in the mirabegron and placebo groups, respectively (Table [3](#Tab3){ref-type="table"}). Among patients with MoCA data available at baseline/EoT, 27.1% (115/425) and 25.8% (106/411) of mirabegron and placebo group patients, respectively, had impaired cognitive function (MoCA total score \<26) at baseline (Fig. [1](#Fig1){ref-type="fig"}). Table 3Change from baseline to EoT in MoCA test total score (SAF)PlaceboMirabegron TotalBaseline, mean (SE)^a^26.8 (0.1)26.9 (0.1)EoT, mean (SE)^b^27.0 (0.1)26.9 (0.1)Adjusted change from baseline, mean (SE)−0.1 (0.1)−0.2 (0.1)95% two-sided CI(−0.4, 0.2)(−0.4, 0.1)*p*-value0.471*CI* confidence interval, *EoT* end of treatment, *MoCA* Montreal Cognitive Assessment, *SAF* safety analysis set, *SE* standard error^a^*N* = 440 for placebo and 443 for mirabegron total^b^*N* = 413 for placebo and 427 for mirabegron totalFig. 1MoCA score at baseline and week 12/EoT. *EoT* end of treatment, *MoCA* Montreal Cognitive Assessment. Impaired cognitive function = MoCA total score \<26 \[[@CR19]\]

End of treatment {#Sec5}
----------------

There were no changes in adjusted mean (SE) MoCA total score from baseline to EoT in the mirabegron group (−0.2 \[0.1\]) or the placebo group (−0.1 \[0.1\]) (Table [3](#Tab3){ref-type="table"}). Changes in subscale scores are shown in Table [4](#Tab4){ref-type="table"}. The number of patients missing scores at EoT were 29 for placebo and 18 for the mirabegron total group. Of the 411 patients receiving placebo and 425 patients receiving mirabegron, 48 patients (24 in each group) had declines of MoCA score of ≥4 points at week 12. The distribution of score changes are shown in Fig. [2](#Fig2){ref-type="fig"}. At week 12/EoT, 24.5% (104/425) and 25.8% (106/411) of mirabegron and placebo patients, respectively, had impaired cognitive function (Fig. [1](#Fig1){ref-type="fig"}). Post hoc analyses showed mirabegron and placebo to be similar with respect to the likelihood of experiencing cognitive decline (Fig. [3](#Fig3){ref-type="fig"}), using the MDC for a community-living elder population found in the literature \[[@CR25]\]. MoCA scores showed no differences in change from baseline to EoT by baseline medical history of depression or antidepressant medication use, or by presence of ≥1 strong anticholinergic concomitant medication as recognized by the Anticholinergic Cognitive Burden scale \[[@CR26]\] (Table [5](#Tab5){ref-type="table"}). Table 4Change from baseline to EoT in MoCA subscale scores (SAF)Change, mean (SD)Placebo (*n* = 411)Mirabegron Total (*n* = 425)Attention Points−0.0 (0.9)−0.1 (0.9)Language Points0.0 (0.7)0.0 (0.7)Naming Points−0.0 (0.4)0.0 (0.4)Visuospatial/Executive Points0.0 (1.0)−0.1 (1.2)Abstraction Points0.0 (0.5)−0.0 (0.5)Delayed Recall Points0.2 (1.4)0.2 (1.3)Orientation Points−0.0 (0.4)−0.0 (0.4)*EoT* end of treatment, *MoCA* Montreal Cognitive Assessment, *SAF* safety analysis set, *SD* standard deviationFig. 2Percentage of patients with indicated MoCA score change at week 12/EoT. *EoT* end of treatment, *MoCA* Montreal Cognitive AssessmentFig. 3Forest plot for MCD of at least −4 points in total MoCA score. *CL* confidence limit, *EoT* end of treatment, *LCL* lower confidence limit, *MCD* minimally clinically important difference, *MoCA* Montreal Cognitive Assessment, *N* number of observations, *RR* relative risk ratio, *UCL* upper confidence limitTable 5MoCA scores for patients with/without use of antidepressant medication, depression diagnosis from medical history, and by use of strong anticholinergic burden concomitant medicationPlacebo (*n* = 411)Mirabegron Total (*n* = 425)Total score at BL, mean (SD)Total score at EoT, mean (SD)Change in Total score, meanTotal score at BL, mean (SD)Total score at EoT, mean (SD)Change in Total score, meanUse of antidepressant medication^a^ No (*n* = 695)26.9 (2.9)27.1 (2.8)0.226.9 (2.7)27.0 (2.7)0.0 Yes (*n* = 141)26.6 (2.6)26.9 (2.4)0.326.5 (3.0)26.6 (2.8)0.2Depression diagnosis from medical history^b^ No (*n* = 683)26.8 (2.9)27.0 (2.7)0.227.0 (2.5)27.0 (2.7)0.0 Yes (*n* = 153)26.9 (2.6)27.1 (2.6)0.126.2 (3.3)26.7 (2.8)0.4Use of anticholinergic burden concomitant medication^c^ No (*n* = 767)26.8 (2.8)27.1 (2.7)0.226.8 (2.7)26.9 (2.7)0.0 Yes (*n* = 69)26.6 (3.5)26.6 (3.1)027.0 (2.9)27.4 (2.4)0.4^a^*N* = 345 for placebo and 350 for mirabegron total for No, *N* = 66 for placebo and 75 for mirabegron total for Yes^b^*N* = 341 for placebo and 342 for mirabegron total for No, *N* = 70 for placebo and 83 for mirabegron total for Yes^c^*N* = 380 for placebo and 387 for mirabegron total for No, *N* = 31 for placebo and 38 for mirabegron total for Yes

Of note, over 300 study participants, or nearly 41%, experienced an increase from one to nine points in MoCA score (Fig. [2](#Fig2){ref-type="fig"}). There were no differences between treatment and placebo groups in MoCA score improvements. The frequency of AEs that are typically seen with antimuscarinics was low for both mirabegron and placebo (Table [6](#Tab6){ref-type="table"}). Table 6Drug-related treatment-emergent adverse events ≥1% in either treatment group (SAF)TEAEs, *n* (%)Placebo (*n* = 442)Mirabegron Total (*n* = 445)Drug-related TEAEs^a^57 (12.9)84 (18.9) Dry mouth7 (1.6)6 (1.3) Nausea3 (0.7)6 (1.3) Constipation4 (0.9)3 (0.7) Diarrhea1 (0.2)5 (1.1) Headache7 (1.6)18 (4.0) Dizziness6 (1.4)2 (0.4) Somnolence1 (0.2)2 (0.4) Escherichia urinary tract infection7 (1.6)9 (2.0) Fatigue10 (2.3)7 (1.6)^a^Possible or probable, as assessed by the investigator, or where relationship was missing*SAF* safety analysis set, *TEAEs* treatment-emergent adverse events

Discussion {#Sec6}
==========

Treatment with mirabegron for 12 weeks had no adverse impact on cognitive function in patients aged ≥65 years, as measured by the MoCA and compared with those randomized to placebo. Together with the efficacy demonstrated during the PILLAR study, these data suggest that mirabegron does not worsen cognition in older adults treated for OAB who are at risk of or concerned about cognitive impairment. Therefore, mirabegron represents a viable alternative for treatment of older patients with OAB, especially for those on anticholinergic medications for other diseases.

In comparison, a systematic review and several subsequent publications have found a strong link between cognitive impairment and anticholinergic potency of medications \[[@CR14], [@CR15], [@CR26], [@CR27]\]. There appears to be a differential effect on cognition between antimuscarinics used in the treatment of OAB, although there is substantial variability in scientific approaches such as duration of observation, outcome measures employed, and populations studied. Several studies have reported that oral oxybutynin has a significant negative effect on cognitive function in healthy adults ≥60 years of age \[[@CR28]--[@CR31]\]. Cognitive impairment has also been reported with tolterodine at therapeutic doses in small numbers of cognitively intact \[[@CR32]--[@CR34]\] and cognitively impaired older people \[[@CR35]\]. In separate studies, cumulative exposure to strong anticholinergics increased the odds of transitioning from normal cognition to MCI in adults ≥65 years \[[@CR36]\] and was associated with an increased risk for dementia and Alzheimer's disease \[[@CR15]\]. Anticholinergics have also been suggested to reduce the likelihood of reverting to normal cognition among those with a diagnosis of MCI \[[@CR36]\]. However, conflicting evidence in older people with dementia suggests that anticholinergics may not affect cognition in these individuals \[[@CR27], [@CR37], [@CR38]\].

It is worth noting that oxybutynin and tolterodine made up the majority of OAB medication use in these prior reports. Other studies support the lack of cognitive effects for trospium in patients ≥75 years \[[@CR39]--[@CR42]\]. Solifenacin at a dose of 10 mg also had no detectable effect on cognition in healthy elderly volunteers ≥65 years \[[@CR29]\] or in those ≥75 years with MCI \[[@CR31]\]. With the exception of a case report of delirium following fesoterodine treatment in an 89-year-old man with renal failure \[[@CR43]\], there do not appear to be reports of cognitive impairment with fesoterodine in patients ≥65 years \[[@CR44], [@CR45]\], or with darifenacin in patients ≥60 years \[[@CR30]\] or ≥65 years \[[@CR46]\]. Newer, longer-acting antimuscarinics may therefore not be associated with cognitive effects; however, caution is warranted because of overall anticholinergic load.

As people aged ≥65 years are frequently under-represented in clinical trials, the results in the PILLAR study, which included a substantial proportion ≥75 years, are clinically relevant. Patients in this study were community dwelling and relatively healthy, as shown by low baseline Charlson Comorbidity Index scores. However, the number of concomitant medications and comorbid conditions observed at baseline in this study are similar to those in the general older population \[[@CR8]\].

The MoCA presents several advantages compared with the MMSE. For example, it includes more executive function and visuospatial items than the MMSE, thus the MoCA provides a more comprehensive assessment across cognitive domains. In addition, the MoCA 5-word recall task is better at probing for subtle memory changes than the MMSE 3-word task \[[@CR47]\]. The improvement in sensitivity in detecting cognitive decline compared with the MMSE has been clearly demonstrated, particularly in stroke studies \[[@CR48], [@CR49]\]. Other advantages of the MoCA are that it can be administered in the clinical setting by a trained rater in 10 min (although training occurred for all sites it is worth noting that this study took place before mandatory MoCA training was introduced by the developers), without relying on specific expertise in neurology, psychiatry, or clinical psychology. The MoCA may therefore be useful to practitioners if they are concerned about cognitive decline in their patients due to an increased anticholinergic burden resulting from multiple medications \[[@CR50]\].

A number of studies have assessed the ability of the MoCA to detect change in healthy and impaired populations. Feeney et al. provided a distribution-based estimate of change from a sample of community-living people aged ≥55 years in Ireland \[[@CR25]\]. This study provided a calculation of the MDC, with the implication that an individual's score would need to change by ≥4 points on the MoCA to be confident that the change was not due to chance or measurement error. In the current study, post hoc analyses utilizing the MDC showed that mirabegron and placebo were similar with respect to the likelihood of experiencing cognitive decline.

Although initially developed for capture of MCI in patients presenting with cognitive complaints due to Alzheimer's disease \[[@CR19]\], the MoCA has also been used to assess cognitive decline associated with other conditions. These include stroke \[[@CR51]\], acquired brain injury \[[@CR52]\], Parkinson's disease \[[@CR53], [@CR54]\], chronic obstructive pulmonary disease \[[@CR55]\], heart failure \[[@CR56]\], complications of diabetes \[[@CR57]\], chronic hemodialysis \[[@CR58]\], and Huntington's disease \[[@CR59]\]. The Huntington Study Group used the MoCA in a trial of dutetrabenazine for treatment of chorea in patients with Huntington's disease. They reported that there was no significant difference in the mean change on the total MoCA score between placebo and the treatment of interest across the 12 weeks of the trial \[[@CR59]\]. This outcome reflects the use of the MoCA in the current study.

The MoCA was developed specifically for detecting decrements in the performance of basic neurocognitive tasks, although it has also been used to track improvements. The current study supports the use of the MoCA for measuring decline in cognitive function as a side effect of OAB treatment and also demonstrates the similarity in general cognitive function outcomes between mirabegron and placebo. While the MoCA has well-established utility as a screening tool for cognitive impairment, it is not a diagnostic test and provides incomplete measurement of the individual core cognitive domains. It should therefore not be viewed as a substitute for more in-depth neuropsychological assessment when domain-specific information is required \[[@CR60]\].

Limitations of the current study include the short study duration and the use of the same version of the MoCA 12 weeks after first administration. This use of the same version is likely reflected in the 41% of patients who improved their MoCA score on subsequent administration (i.e. a training effect). In addition, the study enrolled patients with wet OAB based in the community, so the results are not representative of other elderly patient groups, such as those in nursing homes or hospitalized. Also, Charlson Comorbidity Index scores were very low at baseline, indicating that these community-dwelling patients were generally healthy and unlikely to be frail; thus these findings do not apply to all elderly individuals with OAB.

Conclusions {#Sec7}
===========

Cognitive assessment over 12 weeks using the MoCA in the PILLAR study demonstrates that mirabegron treatment does not contribute to drug-related cognitive side-effects. Furthermore, the pattern of change in cognition over the trial duration in an older OAB trial population does not appear to differ from that of subjects receiving placebo.
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